Diagnostic Performance and Safety of a Novel Ferumoxytol-Enhanced Coronary Magnetic Resonance Angiography
Authors' conclusion
Ferumoxytol-enhanced CMRA demonstrated good diagnostic performance and excellent safety in the diagnosis of significant coronary stenosis, providing an alternative to coronary computed tomography angiography for the diagnosis of coronary artery disease.
Study context
- Population
- Patients with suspected CAD scheduled for invasive coronary angiography (19 males, median age 63 years, 17 with renal insufficiency)
- Participants
- 30 patients
- Comparison
- Ferumoxytol-enhanced coronary magnetic resonance angiography (CMRA) vs invasive coronary angiography
- Outcome
- Diagnostic performance (sensitivity, specificity, PPV, NPV, accuracy) vs invasive coronary angiography
Performance
As reported in the abstract
Diagnostic performance of ferumoxytol-enhanced CMRA
| Test or model | Patient-based sensitivity | Patient-based specificity | Patient-based PPV | Patient-based NPV | Patient-based accuracy | Vessel-based sensitivity | Vessel-based specificity | Vessel-based PPV | Vessel-based NPV | Vessel-based accuracy | Segment-based sensitivity | Segment-based specificity | Segment-based PPV | Segment-based NPV | Segment-based accuracy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferumoxytol-enhanced CMRA | 100.0% | 66.7% | 92.3% | 100.0% | 93.3% | 91.4% | 90.9% | 86.5% | 94.3% | 91.1% | 92.3% | 96.7% | 83.7% | 98.6% | 96.0% |
Ferumoxytol-enhanced CMRA
Patient-based sensitivity100.0%
Patient-based specificity66.7%
Patient-based PPV92.3%
Patient-based NPV100.0%
Patient-based accuracy93.3%
Vessel-based sensitivity91.4%
Vessel-based specificity90.9%
Vessel-based PPV86.5%
Vessel-based NPV94.3%
Vessel-based accuracy91.1%
Segment-based sensitivity92.3%
Segment-based specificity96.7%
Segment-based PPV83.7%
Segment-based NPV98.6%
Segment-based accuracy96.0%
Further findings
Segment visibility and image quality (4-point scale)
- Segments identified by CMRA, of 270
- 252
- Quality score
- 3.6±0.7
Safety
Ferumoxytol-related adverse events · 3-month follow-up
- No ferumoxytol-related adverse event observed
Original publication
Diagnostic Performance and Safety of a Novel Ferumoxytol-Enhanced Coronary Magnetic Resonance Angiography. Circ Cardiovasc Imaging. Published 18 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →